Direct-to-consumer marketing of osteoporosis drugs and bone densitometry

Ann Pharmacother. 2003 Jul-Aug;37(7-8):976-81. doi: 10.1345/aph.1C422.

Abstract

Objective: To determine whether there is an association between a woman's exposure to direct-to-consumer (DTC) advertisements for 2 osteoporosis drugs and presentation for bone densitometry.

Methods: A matched case-control study was conducted between October and December 1998 at an academic primary care clinic in Seattle, WA. Seventeen women from the study population (aged >/=18 y, seen in the previous 2 y at the academic primary care clinic) presented for bone densitometry. All 51 women completed a self-administered questionnaire.

Results: Women familiar with 1 of 2 osteoporosis drugs due to exposure to advertisements had 9 times the odds of densitometry (unadjusted OR 9.3, 95% CI 1.0 to 86). Multivariate analysis, including confounders such as education level and whether a woman had previously had 3 screening tests (mammography, Pap smear, serum cholesterol), revealed a significant and strong association between exposure to advertisements and densitometry (adjusted OR 29, 95% CI 1.6 to 511).

Conclusions: DTC marketing may increase health services utilization. Further independent evaluation of DTC marketing based on available observational evidence is feasible and warranted.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Advertising
  • Aged
  • Alendronate / therapeutic use
  • Bone Density / drug effects*
  • Case-Control Studies
  • Densitometry
  • Female
  • Health Education
  • Humans
  • Logistic Models
  • Marketing of Health Services
  • Middle Aged
  • Osteoporosis / drug therapy*
  • Population
  • Raloxifene Hydrochloride / therapeutic use
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Surveys and Questionnaires

Substances

  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Alendronate